141 related articles for article (PubMed ID: 20367135)
1. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
Kamel S; O'Connor S; Lee N; Filshie R; Nandurkar H; Tam CS
Leuk Lymphoma; 2010 May; 51(5):797-801. PubMed ID: 20367135
[TBL] [Abstract][Full Text] [Related]
2. A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?
Tadmor T; McLaughlin P; Polliack A
Leuk Lymphoma; 2010 May; 51(5):737-8. PubMed ID: 20367567
[No Abstract] [Full Text] [Related]
3. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
[TBL] [Abstract][Full Text] [Related]
4. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
5. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
Chen YB; Hochberg EP; Feng Y; Neuberg D; Rawal B; Motyckova G; Fisher DC; McAfee SL; Spitzer TR; Lacasce AS
Leuk Lymphoma; 2010 May; 51(5):789-96. PubMed ID: 20367136
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract][Full Text] [Related]
7. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
[No Abstract] [Full Text] [Related]
8. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.
Kolstad A; Holte H; Fosså A; Lauritzsen GF; Gaustad P; Torfoss D
Haematologica; 2007 Jan; 92(1):139-40. PubMed ID: 17229653
[TBL] [Abstract][Full Text] [Related]
10. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma.
Katsuya H; Suzumiya J; Sasaki H; Ishitsuka K; Shibata T; Takamatsu Y; Tamura K
Leuk Lymphoma; 2009 Nov; 50(11):1818-23. PubMed ID: 19863173
[TBL] [Abstract][Full Text] [Related]
11. Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy.
Kim T; Choi SH; Kim SH; Jeong JY; Woo JH; Kim YS; Sung H; Kim MN; Yoon DH; Suh C; Lee SO
Ann Hematol; 2013 Jan; 92(2):231-8. PubMed ID: 23053189
[TBL] [Abstract][Full Text] [Related]
12. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
13. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.
Yokoyama H; Watanabe T; Maruyama D; Kim SW; Kobayashi Y; Tobinai K
Int J Hematol; 2008 Nov; 88(4):443-447. PubMed ID: 18855101
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
16. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
17. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
Kurokawa T; Kaya H; Yoshida T
J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
19. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
Gutiérrez-García G; Colomo L; Villamor N; Arenillas L; Martínez A; Cardesa T; García-Herrera A; Setoain X; Rodríguez S; Ghita G; Abrisqueta P; Giné E; Bosch F; Campo E; Montserrat E; López-Guillermo A
Leuk Lymphoma; 2010 Jul; 51(7):1225-32. PubMed ID: 20497002
[TBL] [Abstract][Full Text] [Related]
20. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]